Federal drug price negotiation law expands under second Trump administration

A re-elected Trump administration will expand Medicare’s drug price negotiation powers to cover more therapies by 2027, accelerating existing reforms. This follows Trump’s stated intent to target pharmaceutical profits and reduce healthcare costs.

Implied probability (Yes)

70%